BioAge Labs has successfully priced an upsized underwritten public offering of 5,897,435 shares of its common stock, generating approximately $115 million in gross proceeds. The company granted the underwriters a 30-day option to purchase up to an additional 884,615 shares. The offering was managed by Goldman Sachs & Co. LLC, Piper Sandler and Citigroup, and is expected to close on January 23, 2026, subject to customary closing conditions under a registration statement on Form S-3 that became effective in late 2025.

BioAge intends to deploy the net proceeds, together with existing cash, cash equivalents and marketable securities, to fund research, clinical and process development and manufacturing of its lead candidate BGE-102, an orally available NLRP3 inhibitor currently in a Phase 1 SAD/MAD trial with topline data for additional cohorts expected in the first half of 2026. Funds will also support the development of long-acting injectable and oral APJ agonists for obesity, expansion of preclinical aging-biology programs and general corporate purposes, including working capital, capital expenditures and debt reduction.